• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Day One Biopharmaceuticals Inc (NQ: DAWN )

    16.18 +0.30 (+1.89%)
    Streaming Delayed Price Updated: 11:08 AM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Day One Biopharmaceuticals Inc

    < Previous 1 2 3 4 5 Next >
    Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
    FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
    Via Talk Markets
    Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Sale of Priority Review Voucher for $108 Million
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Analyst Ratings for Day One Biopharmaceutical
    Via Benzinga
    The Latest Analyst Ratings for Day One Biopharmaceutical
    Via Benzinga
    DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
    DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Day One Reports First Quarter 2024 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Where Day One Biopharmaceutical Stands With Analysts
    Via Benzinga
    Analyst Ratings for Day One Biopharmaceutical
    Via Benzinga
    Day One Announces Two New Appointments to Board of Directors
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
    Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting 
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Dow Up Over 340 Points As Stocks Snap Back
    The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
    U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    Priority review granted with PDUFA target action date of April 30, 2024 
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
    Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
    Via Benzinga
    Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    $3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying
    Although US stocks closed higher on Monday, there were a few notable insider trades. 
    Via Benzinga
    Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
    The Nasdaq held near 52-week highs while small caps ramped up. 
    Via Investor's Business Daily
    Day One Announces Pricing of Public Offering of Common Stock
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    Day One Announces Proposed Public Offering of Common Stock
    From Day One Biopharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.